The role of doxorubicin in non-viral gene transfer in the lung

Biomaterials

Volumn 30, Issue 10, 2009, Pages 1971-1977

  Griesenbach, Uta ^a,b   Meng, Cuixiang ^a,b   Farley, Raymond ^a,b   Gardner, Aaron ^a,b   Brake, Maresa A ^a,b   Frankel, Gad M ^a   Gruenert, Dieter C ^c,d,e   Cheng, Seng H ^f   Scheule, Ronald K ^f   Alton, Eric W F W ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UK Cystic Fibrosis Gene Therapy Consortium   (United Kingdom)

^c CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^f Genzyme Ltd   (United Kingdom)

Author keywords

Gene transfer; In vitro test; In vivo test; Lipid; Lung

Indexed keywords

A549 CELLS; ADENO-ASSOCIATED VIRUS; AIRWAY EPITHELIAL CELLS; CANCER CHEMOTHERAPIES; CATIONIC LIPIDS; CYSTIC FIBROSIS; DOXORUBICIN; ELONGATION FACTORS; IN VITRO TEST; IN VIVO TEST; IN-VIVO; INTRAPERITONEALLY; KNOCKOUT MOUSE; LIPID; LUNG; NON-VIRAL; PROTEASOME INHIBITORS; REPORTER GENES;

BIOLOGICAL ORGANS; CELL CULTURE; CHEMOTHERAPY; ENZYME ACTIVITY; GENE EXPRESSION; NUCLEIC ACIDS; ORGANIC ACIDS; TESTING;

GENE TRANSFER;

ACETIC ACID DERIVATIVE; CATION; DOXORUBICIN; ELONGATION FACTOR 1ALPHA; LIPID; LUCIFERASE; N ACETYL LEVO LEUCINYL LEVO LEUCINAL LEVO NORLEUCINAL; PARVOVIRUS VECTOR; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CELL LINE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOMEGALOVIRUS; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; KNOCKOUT MOUSE; LUNG; MALE; MOUSE; NEBULIZATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; RESPIRATORY EPITHELIUM; TREATMENT RESPONSE;

ANIMALS; CELL LINE; CYSTIC FIBROSIS; DOXORUBICIN; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LUNG; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE ELONGATION FACTOR 1; PROMOTER REGIONS, GENETIC;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 59649105951     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2008.12.037     Document Type: Article

References (21)

1. Ding W., Yan Z., Zak R., Saavedra M., Rodman D.M., and Engelhardt J.F. Second-strand genome conversion of adeno-associated virus type 2 (AAV-2) and AAV-5 is not rate limiting following apical infection of polarized human airway epithelia. J Virol 77 13 (2003) 7361-7366
2. Yan Z., Lei-Butters D.C., Zhang Y., Zak R., and Engelhardt J.F. Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum Gene Ther 18 1 (2007) 81-87
3. Zhang L.N., Karp P., Gerard C.J., Pastor E., Laux D., Munson K., et al. Dual therapeutic utility of proteasome modulating agents for pharmaco-gene therapy of the cystic fibrosis airway. Mol Ther 10 6 (2004) 990-1002
4. Kim J., Chen C.P., and Rice K.G. The proteasome metabolizes peptide-mediated nonviral gene delivery systems. Gene Ther 12 21 (2005) 1581-1590
5. Kim K.I., Kang J.H., Chung J.K., Lee Y.J., Jeong J.M., Lee D.S., et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 48 9 (2007) 1553-1561
6. Harvey B.G., Leopold P.L., Hackett N.R., Grasso T.M., Williams P.M., Tucker A.L., et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J Clin Invest 104 9 (1999) 1245-1255
7. Sumner-Jones S.G., Gill D.R., and Hyde S.C. Lack of repeat transduction by recombinant adeno-associated virus type 5/5 vectors in the mouse airway. J Virol 81 22 (2007) 12360-12367
8. Lee E.R., Marshall J., Siegel C.S., Jiang C., Yew N.S., Nichols M.R., et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 7 14 (1996) 1701-1717
9. Alton E.W., Stern M., Farley R., Jaffe A., Chadwick S.L., Phillips J., et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 353 9157 (1999) 947-954
10. Yonemitsu Y., Kitson C., Ferrari S., Farley R., Griesenbach U., Judd D., et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 18 9 (2000) 970-973
11. Yan Z., Zak R., Zhang Y., Ding W., Godwin S., Munson K., et al. Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia. J Virol 78 6 (2004) 2863-2874
12. Kunzelmann K., Schwiebert E.M., Zeitlin P.L., Kuo W.L., Stanton B.A., and Gruenert D.C. An immortalized cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation. Am J Respir Cell Mol Biol 8 5 (1993) 522-529
13. Zhou L., Dey C.R., Wert S.E., DuVall M.D., Frizzell R.A., and Whitsett J.A. Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266 5191 (1994) 1705-1708
14. Hyde S.C., Pringle I.A., Abdullah S., Lawton A.E., Davies L.A., Varathalingam A., et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 26 5 (2008) 549-551
15. Griesenbach U., Meng C., Farley R., Cheng S.H., Scheule R.K., Davies M.H., et al. In vivo imaging of gene transfer to the respiratory tract. Biomaterials 29 10 (2008) 1533-1540
16. Buckley S.M., Howe S.J., Wong S.P., Buning H., McIntosh J., Baker A., et al. Luciferin detection after intra-nasal vector delivery is improved by intra-nasal rather than intra-peritoneal luciferin administration. Hum Gene Ther (2008) doi:10.1089/hgt.2008.023 [ahead of print]
17. Binaschi M., Bigioni M., Cipollone A., Rossi C., Goso C., Maggi C.A., et al. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 1 2 (2001) 113-130
18. Chen J.J., Chou C.W., Chang Y.F., and Chen C.C. Proteasome inhibitors enhance trail-induced apoptosis through the intronic regulation of DR5: involvement of NF-{kappa}B and reactive oxygen species-mediated p53 activation. J Immunol 180 12 (2008) 8030-8039
19. Takemura G., and Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49 5 (2007) 330-352
20. Tejada-Berges T., Granai C.O., Gordinier M., and Gajewski W. Caelyx/Doxil for the treatment of metastatic ovarian and breast cancer. Expert Rev Anticancer Ther 2 2 (2002) 143-150
21. Charrois G.J., and Allen T.M. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta 1609 1 (2003) 102-108